{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-253851","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2026-06-02T21:15:12+00:00","discovered_at":"2026-06-02T21:16:00.540773+00:00","generated_at":"2026-06-02T21:16:26.383586+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Court invalidates two CINVANTI patents; Heron to appeal to Federal Circuit","bullets":["U.S. District Court for Delaware ruled claims of Patents 12,115,255 and 12,290,520 invalid on June 1, 2026.","Decision does not affect prior settlements for CINVANTI or APONVIE injectable emulsions.","Heron intends to appeal to the Federal Circuit, a court specializing in patent disputes.","CEO Craig Collard said company will vigorously pursue appeal and all available remedies.","Litigation with Azurity (formerly Slayback) involves a generic version of CINVANTI."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253851","json":"https://secwatch.observer/filing/0001193125-26-253851.json","markdown":"https://secwatch.observer/filing/0001193125-26-253851.md","text":"https://secwatch.observer/filing/0001193125-26-253851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/0001193125-26-253851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312526253851/hrtx-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:16:26.383586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}